Wednesday, July 8, 2026
🇺🇸 FDA

Patent directory · USPTO A61K / A61P

Patents matching “Mirati Therapeutics, Inc.”

34 pharma patents match "Mirati Therapeutics, Inc." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 34
Index total 30,257
Page 2 / 2

Quick answer

This filtered view shows 34 pharmaceutical patents matching "Mirati Therapeutics, Inc." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

34 results for “Mirati Therapeutics, Inc.” · 30,257 patents in full index Clear search

  1. US 11220509

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Jan 11, 2022 · Expires Jan 6, 2042

    granted

  2. US 11091495

    Substituted imidazo[1,2-c]pyrimidines as PRC2 inhibitors

    Mirati Therapeutics, Inc. · Granted Aug 17, 2021 · Expires Aug 12, 2041

    granted

  3. US 10689377

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Jun 23, 2020 · Expires Jun 18, 2040

    granted

  4. US 10647715

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted May 12, 2020 · Expires May 7, 2040

    granted

  5. US 10633381

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Apr 28, 2020 · Expires Apr 23, 2040

    granted

  6. US 10266542

    EZH2 inhibitors

    Mirati Therapeutics, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

    granted

  7. US 10233152

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Mar 19, 2019 · Expires Mar 14, 2039

    granted

  8. US 10125134

    KRas G12C inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 13, 2018 · Expires Nov 8, 2038

    granted

  9. US 10059668

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Aug 28, 2018 · Expires Aug 23, 2038

    granted

  10. US 9809541

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Nov 7, 2017 · Expires Nov 2, 2037

    granted

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.